Department of Surgery, 1322Rijnstate Hospital, Arnhem, the Netherlands.
Department of Surgery, Antonius Hospital, Sneek, the Netherlands.
Vascular. 2021 Feb;29(1):108-115. doi: 10.1177/1708538120943319. Epub 2020 Jul 23.
Edge stenoses are the predominant limitation of self-expanding covered stent treatment of superficial femoral artery (SFA) occlusive disease, necessitating reinterventions. Angioplasty of an edge stenosis is associated with a high recurrence rate. Drug-coated balloon (DCB) treatment of edge stenoses might improve outcomes by decreasing the incidence of restenosis.
The aim of this study was to evaluate the outcomes of using a DCB for the treatment of edge stenoses after self-expanding covered stent placement for SFA occlusive disease.
We performed a retrospective analysis of patients treated with a DCB for edge stenoses after self-expanding covered stent placement. The primary endpoint was primary patency at one year. The secondary endpoints included procedure-related complications, secondary patency, and freedom from target lesion revascularization (TLR).
A total of 21 patients with 28 edge stenoses were included. The time from primary treatment to treatment of the edge stenosis was 19 months (interquartile range (IQR) 8; 52 months). Primary patency and assisted primary patency at one year were 66.7% with a secondary patency of 90.9%. Freedom from TLR was 86.1%, and freedom from clinically driven TLR was 89.4%. Four patients presented with a hemodynamically significant restenosis, and three of those patients had an occlusion. Median time to failure was six months (IQR 3.5; 7.0 months), and median time to occlusion was four months (IQR 3.0; 6.0 months).
The treatment of edge stenoses using a DCB is associated with a safe one-year outcome; however, this has to be confirmed in larger prospective studies. The continuous surveillance of patients is indicated.
边缘狭窄是导致股浅动脉(SFA)闭塞性疾病自膨式覆膜支架治疗的主要限制因素,需要再次介入治疗。边缘狭窄处的血管成形术与高复发率相关。药物涂层球囊(DCB)治疗边缘狭窄可能通过降低再狭窄发生率来改善治疗效果。
本研究旨在评估自膨式覆膜支架治疗股浅动脉闭塞性疾病后,使用 DCB 治疗边缘狭窄的效果。
我们对接受 DCB 治疗自膨式覆膜支架治疗后边缘狭窄的患者进行了回顾性分析。主要终点为一年时的初始通畅率。次要终点包括与手术相关的并发症、二级通畅率和免于靶病变血运重建(TLR)。
共纳入 21 例 28 处边缘狭窄患者。从初次治疗到治疗边缘狭窄的时间为 19 个月(四分位间距(IQR)8;52 个月)。一年时的初始通畅率和辅助初始通畅率分别为 66.7%和 90.9%。免于 TLR 的比例为 86.1%,免于临床驱动的 TLR 的比例为 89.4%。4 例患者出现血流动力学意义上的再狭窄,其中 3 例发生闭塞。失败的中位时间为 6 个月(IQR 3.5;7.0 个月),闭塞的中位时间为 4 个月(IQR 3.0;6.0 个月)。
使用 DCB 治疗边缘狭窄的安全性在一年时得到了验证,但这需要在更大的前瞻性研究中得到证实。建议对患者进行持续监测。